RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma Ltd. regained the ex-North America rights to RHB-102 through a mutual agreement with Hyloris Pharmaceuticals SA to terminate the License & Development Agreement, effective October 15, 2026. Hyloris agreed to pay RedHill a one-time $200,000 break-up fee.
The terminated agreement covered exclusive rights to RHB-102 across all indications and territories outside North America. RedHill now has full worldwide rights to the once-daily, proprietary, bimodal extended-release oral tablet formulation of ondansetron, a 5-HT3 antagonist. The company says it continues late-stage development for oncology support and GI indications, including GLP-1/GIP-associated GI intolerance, and is exploring potential partnerships.
RedHill Biopharma Ltd. said its partner, the University of Oklahoma, received a five-year, $2.9 million National Cancer Institute grant planned to fund clinical trials of opaganib after CAR T-cell therapy for ultra-high-risk multiple myeloma. The planned Phase 1b trial will enroll up to 18 patients to assess safety and determine an opaganib dose; a subsequent Phase 2 trial plans to enroll up to 21 additional patients to seek preliminary evidence of effectiveness.
The trials are planned in partnership with RedHill, which is expected to provide opaganib, and Lentigen Technology, Inc., which developed the CAR construct. CAR T cells will be manufactured on the University of Oklahoma campus. Opaganib is investigational and is not available for commercial distribution.
RedHill Biopharma Ltd. filed a prospectus supplement increasing the maximum aggregate offering amount of American Depositary Shares it may issue and sell from time to time under its at-the-market offering agreement with H.C. Wainwright & Co., LLC. Each American Depositary Share represents 10,000 ordinary shares. The report is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.
RedHill Biopharma Ltd. may offer and sell additional American Depositary Shares with an aggregate offering price of up to $2,587,409 from time to time through H.C. Wainwright & Co. under its At The Market Offering Agreement. Each ADS represents 10,000 ordinary shares. This amount is in addition to $49,690.55 of ADSs previously sold under the agreement.
During the 12 calendar months prior to and including this supplement, RedHill sold 54,954 ADSs for aggregate gross proceeds of $49,690.55. The company states its non-affiliate public float had an aggregate market value of $7,911,299.70, based on 87,903,331,000 ordinary shares held by non-affiliates, represented by 8,790,333 ADSs, and a $0.90 per-ADS closing price on August 31, 2026. While its public float remains below $75.0 million, sales under the registration statement cannot exceed one-third of the public float in any 12-calendar-month period. The last reported ADS sale price on October 9, 2026, was $0.539.
RedHill Biopharma Ltd. received Nasdaq’s notice on October 6, 2026, granting an additional 180 calendar days, through April 5, 2027, to regain compliance with the $1.00 per-share minimum bid-price requirement. The earlier compliance period ran through October 5, 2026, following Nasdaq’s April 8, 2026 notice that the ADS closing bid had been below $1.00 for 30 consecutive business days.
The extension has no immediate effect on the listing or trading of RedHill’s ADSs, which continue to trade on The Nasdaq Capital Market under RDHL. Nasdaq will confirm compliance if, before April 5, 2027, the ADS closing bid is at least $1.00 per share for a minimum of 10 consecutive business days. RedHill meets the continued-listing requirement for market value of publicly held shares and all other applicable initial-listing requirements except the minimum bid requirement.
RedHill Biopharma Ltd. Chief Operating Officer Gilead Raday reported acquiring 27,560,000 American Depository Shares through a derivative conversion on October 1, 2026; 131,690,000 American Depository Shares were reported following that entry. On the same date, a trustee sold 1,431 ADS, representing 14,310,000 ordinary shares, at $0.465 per ADS ($0.0000465 per ordinary share) to satisfy tax withholding on vesting of 4,187 RSUs. The sale was under a sell-to-cover policy and was not a discretionary trade by Raday; 176,910,000 ordinary shares were reported following the sale.
RedHill Biopharma Ltd. completed the sale of its 70% interest in Talicia Holdings Inc. to a subsidiary of Apotex Health Corp. on August 27, 2026, receiving an upfront $18.0 million upon completion and up to an additional $35.0 million in potential payments based on worldwide net sales milestones. A RedHill subsidiary also entered a transition services agreement with Apotex.
On August 28, 2026, a RedHill subsidiary entered a License and Commercial Supply Agreement with Ferring Pharmaceuticals for exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq. RedHill paid $12 million upfront, agreed to tiered royalties and potential sales milestone and other contingent payments, and acquired existing Rebyota inventory under deferred payment terms. RedHill believes its stockholders’ equity exceeded $5 million as of September 30, 2026, following these transactions and other third-quarter movements.
RedHill Biopharma Ltd. acquired exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq for an upfront $12 million, plus future milestones and tiered royalties of 5% to 20% on net sales. RedHill also agreed to buy existing Rebyota inventory and make minimum annual purchase commitments during 2027 through 2029. In August 2026, it sold its 70% interest in Talicia Holding Inc. to Apotex for $18 million upfront cash plus up to $35 million in worldwide net-sales milestones. Rebyota and Clenpiq had combined 2025 net sales of approximately $37.5 million under Ferring.
For the six months ended June 30, 2026, continuing-operations revenue was zero versus $0.3 million in 2025, and net loss was $6.1 million versus $4.1 million. Net cash used in operating activities was $4.6 million versus $5.0 million. The cash balance was $5.3 million as of June 30, including cash, cash equivalents, short-term bank deposits and restricted cash.
Management said current resources are insufficient to fund development until sustainable positive cash flows and that additional funding is required. It said conditions may cast significant doubt, or raise substantial doubt under PCAOB standards, about RedHill’s ability to continue as a going concern. August and September transactions brought an approximately $6 million net cash inflow, improving liquidity.
RedHill Biopharma Ltd. (RDHL) reported that a subsidiary entered into a License and Commercial Supply Agreement with Ferring Pharmaceuticals granting RedHill exclusive global commercialization rights to Rebyota® and exclusive U.S. rights to Clenpiq®. The agreement runs for an initial 13 years with automatic two-year renewals.
RedHill paid Ferring a fully funded $12 million upfront fee, financed from the previously announced $18 million cash received from the Talicia® divestiture, and agreed to tiered royalties of 5%–20% on net sales plus capped sales milestones and other contingent payments. Ferring will continue to manufacture and supply the products, while RedHill will exclusively commercialize them in the applicable territories. Rebyota and Clenpiq together generated approximately $37.5 million in U.S. net sales in 2025, and RedHill states that these assets, combined with the Talicia divestiture, complete a strategic repositioning of its commercial gastrointestinal business.
RedHill Biopharma Ltd. (RDHL) has divested its Talicia business by selling its 70% interest in Talicia Holdings Inc. to a subsidiary of Apotex Health Corp. Apotex, which already held the remaining 30%, will now own 100% of Talicia.
RedHill received an upfront cash payment of $18 million and may receive up to an additional $35 million in payments tied to worldwide net sales milestones. The company states that this transaction is intended to strengthen liquidity and fund the next phase of its commercial expansion, including new FDA-approved gastrointestinal products.
The agreement includes a five-year non-compete covenant in the U.S. and its territories relating to Talicia and competing products. RedHill, through a subsidiary, also entered into a Transition Services Agreement under which it will provide certain transition services to Apotex for an initial six-month period, with an option for Apotex to extend for an additional three months for limited services.